InvestSMART

Dimerix Limited (ASX: DXB) - Share Price

Current share price for DXB : $0.200 0.01 (4.76%)+

Dimerix Limited (DXB) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a clinical-stage biopharmaceutical company focused on improving the lives of patients with inflammatory diseases, including kidney disease. The company is developing its proprietary Phase 3 product candidate DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and DMX-700 for orphan respiratory / renal Disease. Both DMX-200 and DMX-700 were identified using Dimerix's proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), a scalable and globally applicable technology platform that enables the understanding of receptor interactions to rapidly screen and identify new drug opportunities.

DXB General Information +

ASX Code DXB
Website http://www.dimerix.com
Industry/Sector Biotechnology
Market Cap ($M) 120
DXB Share Price $0.200
Day High $0.210
Day Low $0.200
Last Close $0.210
DXB Share Price Movement $0.01 ( 4.76% )
Prices as at 16:40, 4 Nov 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Dimerix Limited (DXB) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Dimerix Limited (DXB) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Dimerix Limited (DXB) price-sensitive announcements

DXB - Dimerix Quarterly Activities Report and Appendix 4C
Dimerix Limited (ASX: DXB) reported for the quarter ended 30 September 2026 (Q1 FY27) that
Dimerix Limited (DXB)
29 Oct 2026 | 8:31 AM
DXB - New Data Supports Biological Rationale for DMX-200 in FSGS
Dimerix announced new independent human data presented at Kidney Week 2026 that strengthen
Dimerix Limited (DXB)
23 Oct 2026 | 9:27 AM
DXB - DMX-200 First 100 Patients Complete Phase 3 Trial Treatment
Dimerix Limited announced that the first 100 patients in its pivotal ACTION3 Phase 3 trial
Dimerix Limited (DXB)
16 Oct 2026 | 8:52 AM
DXB - First Patient Reaches Four Years in DMX-200 Clinical Program
Dimerix Limited announced that the first patient has completed four years in the DMX-200 c
Dimerix Limited (DXB)
5 Oct 2026 | 8:56 AM

Dimerix Limited (DXB) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Dimerix Limited (DXB)
ORDINARY FULLY PAID
 Health Care $120 Dimerix Quarterly Activities Report and Appendix 4C 29 Oct 2026 8:31AM $0.205 $0.200 fallen by 2.44%
Dimerix Limited (DXB)
ORDINARY FULLY PAID
 Health Care $120 New Data Supports Biological Rationale for DMX-200 in FSGS 23 Oct 2026 9:27AM $0.205 $0.200 fallen by 2.44%
Dimerix Limited (DXB)
ORDINARY FULLY PAID
 Health Care $120 2026 AGM Notice of Meeting, Letter of Access and Proxy Form 22 Oct 2026 8:44AM $0.210 $0.200 fallen by 4.76%
Dimerix Limited (DXB)
ORDINARY FULLY PAID
 Health Care $120 Dimerix Announces Board Chair Transition 19 Oct 2026 8:30AM $0.220 $0.200 fallen by 9.09%
Dimerix Limited (DXB)
ORDINARY FULLY PAID
 Health Care $120 DMX-200 First 100 Patients Complete Phase 3 Trial Treatment 16 Oct 2026 8:52AM $0.210 $0.200 fallen by 4.76%
Dimerix Limited (DXB)
ORDINARY FULLY PAID
 Health Care $120 Dimerix at Canaccord Drug & Device and Ignite Conferences 12 Oct 2026 8:32AM $0.220 $0.200 fallen by 9.09%

DXB Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$29.81 -$5.00 110.60% 0.00 0.00 0.00% 0.0%
2025A -$13.25 -$2.40 -37.40% 0.00 0.00 0.00% 0.0%
2024A -$17.08 -$3.80 -11.10% 0.00 0.00 0.00% 0.0%

DXB Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
CSL Limited (CSL) $96,534M 0.7309 -0.4395 0.0602 12.4623 22.2350 20.9730 2.11% 2.12% 2.19%
Dimerix Limited (DXB) $126M 1.1059 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Mesoblast Limited (MSB) $2,811M -0.4501 0.0000 0.0000 0.0000 0.0000 981.8182 0.00% 0.00% 0.00%
PYC Therapeutics Limited (PYC) $1,871M -0.3971 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $4,452M -1.3893 0.0000 -0.5230 0.0000 154.0636 322.9630 0.00% 0.00% 0.00%

DXB Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 -8.54 0.00
Market 0.30 13.10 1.02 0.74
Sector 0.76 34.60 2.26 2.03

DXB Directors

Name Position Start Date
Dr Nina Webster Chief Executive Officer, Managing Director 27 Aug 2018
Dr Sonia Maria Poli Non-Executive Director 3 Jul 2015
Mr Clinton Snow Non-Executive Director 1 May 2023
Mr Hugh Alsop Non-Executive Director, Interim Chairman 1 May 2017

Dimerix Limited (DXB) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
12 Dec 2025 SNOW, Clinton Issued Options 300,000 $0.321 $96,300.000
12 Dec 2025 ALSOP, Hugh Issued Options 300,000 $0.321 $96,300.000
12 Dec 2025 WEBSTER, Nina Issued Options 2,500,000 $0.437 $1,093,500.000

See all changes in directors' interest & trades for Dimerix Limited (DXB) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

DXB Management

Name Position
Michael (Mike) Tonroe Chief Financial Officer,Company Secretary
Dr David Fuller Chief Medical Officer
Dr Robert Shepherd Chief Operating Officer

DXB Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Dimerix Limited (DXB). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
91,640,374 (15.26%) Mr Peter Meurs

DXB Calendar of Events

Date Event
26 August 2027 Report (Annual)
26 August 2027 Report (Prelim)
25 February 2027 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.